The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety

BACKGROUND: The low cost of thiazolidinediones makes them a potentially valuable therapeutic option for the > 300 million economically disadvantaged persons worldwide with type 2 diabetes mellitus. Differential selectivity of thiazolidinediones for peroxisome proliferator-activated receptors in t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cardiovasc Diabetol
Main Authors: Leonard, Charles E., Brensinger, Colleen M., Dawwas, Ghadeer K., Deo, Rajat, Bilker, Warren B., Soprano, Samantha E., Dhopeshwarkar, Neil, Flory, James H., Bloomgarden, Zachary T., Gagne, Joshua J., Aquilante, Christina L., Kimmel, Stephen E., Hennessy, Sean
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7041286/
https://ncbi.nlm.nih.gov/pubmed/32098624
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-020-00999-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados